Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / TLR2

TLR2

Basics

Aliases:
This biomarker is also known as:
  • toll-like receptor 2,
  • TIL4,
  • toll/interleukin-1 receptor-like protein 4,
  • toll/interleukin 1 receptor-like 4,
  • Toll/interleukin-1 receptor-like protein 4,
  • CD282 antigen,
  • CD282,

View in BioMuta

Description…

TLR2, or toll-like receptor 2, is a member of the Toll-like receptor (TLR) family which plays a fundamental role in pathogen recognition and activation of innate immunity. TLR2 is involved in the innate immune response to bacterial lipoproteins and other microbial cell wall components. TLR2 also plays a role in NF-kappa-B activation, cytokine secretion and the inflammatory response.

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

TLR2 gene polymorphisms have been related to increased susceptibility to cancer development in various organs, including breast cancer.

Performance Comment

TLR2 was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html